Lenalidomide for the Treatment of Relapsed and Refractory Multiple Myeloma

DSpace/Manakin Repository

Lenalidomide for the Treatment of Relapsed and Refractory Multiple Myeloma

Citable link to this page

 

 
Title: Lenalidomide for the Treatment of Relapsed and Refractory Multiple Myeloma
Author: Görgün, Güllü; Nijhof, Inger S; Raymakers, Reinier A; Lokhorst, Henk M; Groen, Richard W.j.; Jakubikova, Jana; Mitsiades, Constantine S; Hideshima, Teru; Laubach, Jacob; Richardson, Paul Gerard Guy; Anderson, Kenneth Carl; van de Donk, Niels WCJ

Note: Order does not necessarily reflect citation order of authors.

Citation: van de Donk, Niels W. C. J., Güllü Görgün, Richard W. J. Groen, Jana Jakubikova, Constantine S. Mitsiades, Teru Hideshima, Jacob Laubach et al. 2012. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Management and Research 4:253-268.
Full Text & Related Files:
Abstract: Lenalidomide is an amino-substituted derivative of thalidomide with direct antiproliferative and cytotoxic effects on the myeloma tumor cell, as well as antiangiogenic activity and immunomodulatory effects. Together with the introduction of bortezomib and thalidomide, lenalidomide has significantly improved the survival of patients with relapsed and refractory myeloma. The most common adverse events associated with lenalidomide include fatigue, skin rash, thrombocytopenia, and neutropenia. In addition, when lenalidomide is combined with dexamethasone or other conventional cytotoxic agents, there is an increase in the incidence of venous thromboembolic events. There is now evidence that continued treatment with lenalidomide has a significant impact on survival by improving the depth and duration of response. This highlights the value of adverse event management and appropriate dose adjustments to prevent toxicity, and of allowing continued treatment until disease progression. In this review, we will discuss the different lenalidomide-based treatment regimens for patients with relapsed/refractory myeloma. This is accompanied by recommendations of how to manage and prevent adverse events associated with lenalidomide-based therapy.
Published Version: doi:10.2147/CMAR.S27087
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430086/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10533598
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters